- Home
- CMA vs STVN Comparison
CMA vs STVN Comparison
Compare CMA & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- STVN
- Stock Information
- Founded
- CMA 1849
- STVN 1949
- Country
- CMA United States
- STVN Italy
- Employees
- CMA N/A
- STVN N/A
- Industry
- CMA Major Banks
- STVN Containers/Packaging
- Sector
- CMA Finance
- STVN Consumer Discretionary
- Exchange
- CMA Nasdaq
- STVN Nasdaq
- Market Cap
- CMA 7.1B
- STVN 6.6B
- IPO Year
- CMA N/A
- STVN 2021
- Fundamental
- Price
- CMA $56.13
- STVN $21.77
- Analyst Decision
- CMA Hold
- STVN Buy
- Analyst Count
- CMA 20
- STVN 6
- Target Price
- CMA $61.55
- STVN $25.08
- AVG Volume (30 Days)
- CMA 1.4M
- STVN 326.1K
- Earning Date
- CMA 07-18-2025
- STVN 05-08-2025
- Dividend Yield
- CMA 4.97%
- STVN 0.27%
- EPS Growth
- CMA 4.95
- STVN N/A
- EPS
- CMA 5.29
- STVN 0.50
- Revenue
- CMA $3,234,000,000.00
- STVN $1,215,562,040.00
- Revenue This Year
- CMA $7.20
- STVN $8.42
- Revenue Next Year
- CMA $3.01
- STVN $10.44
- P/E Ratio
- CMA $10.80
- STVN $44.76
- Revenue Growth
- CMA N/A
- STVN 3.81
- 52 Week Low
- CMA $45.32
- STVN $16.56
- 52 Week High
- CMA $73.45
- STVN $25.75
- Technical
- Relative Strength Index (RSI)
- CMA 48.19
- STVN 44.14
- Support Level
- CMA $55.00
- STVN $21.97
- Resistance Level
- CMA $57.60
- STVN $24.43
- Average True Range (ATR)
- CMA 1.04
- STVN 1.23
- MACD
- CMA -0.13
- STVN -0.26
- Stochastic Oscillator
- CMA 27.24
- STVN 5.91
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.